

COVID treatment and in-hospital length of stay inequalities between race in the US over time

Benjamin M. Althouse, PhD, ScM^{1,2,3}, Charlotte Baker, DrPH, MPH, CPH¹, Peter D Smits, PhD¹, Samuel Gratzl, PhD¹, Ryan H Lee, MD¹, Brianna M Goodwin Cartwright, MS¹, Michael Simonov, MD^{1,4}, Michael D Wang, MD¹, and Nicholas L Stucky, MD, PhD¹

¹Truveta, Inc, Bellevue, WA

²University of Washington, Seattle, Washington

³New Mexico State University, Las Cruces, New Mexico

⁴Yale School of Medicine, New Haven, CT

*nicholass@truveta.com

ABSTRACT

Introduction: Demonstrated health inequalities persist in the United States. SARS-CoV-2 (COVID) has been no exception, with access to treatment and hospitalization differing across race or ethnic group. Here we aim to assess differences in treatment with remdesivir and hospital length of stay across four waves of the pandemic.

Methods: Using a subset of the Truveta data we examine odds ratios (OR) of in-hospital remdesivir treatment and risk ratios (RR) of in-hospital length of stay between Black or African American (Black) to white patients. We adjusted for confounding factors such as age, sex, and comorbidity status.

Results: There were statically significant lower rates of remdesivir treatment and longer in-hospital lengths of stay comparing Black patients to white patients early in the pandemic (OR for treatment: 0.88, 95% confidence interval [CI]: 0.80, 0.96; RR for length of stay: 1.17, CI: 1.06, 1.21). Rates became close to parity between groups as the pandemic progressed.

Conclusions: While inpatient remdesivir treatment rates increased and length of stay decreased over the beginning course of the pandemic, there are still inequalities in patient care.

Corresponding author:

Dr Nicholas Stucky

Truveta, Inc

1745 114th Ave SE, Bellevue, WA 98004

Email: nicholass@truveta.com

1 Introduction

2 Inequalities in medical care in the United States (US) are widespread across socioeconomic (SES) and racial bounds¹. The
3 SARS-CoV-2 (COVID) pandemic has only intensified these inequalities¹. Zelner et al.² found a 5.5-fold increase in incidence
4 and age-standardized mortality in Black or African American patients (Black) as compared to white patients, though their study
5 was limited to the state of Michigan. In a systematic review of COVID outcomes, Mackey et al.³ showed that Black patients
6 experienced higher rates of COVID infection and overall mortality, but not COVID-related mortality. However, no identified
7 studies examined rates of COVID treatment or length of inpatient hospital stay (LoS). With ongoing calls for healthcare reform,
8 racial equality, and the end of systemic racism, it is of key importance to identify areas where systematic inequalities have been
9 bettered, where they still exist, and how they have changed over time.

10 Given the growing availability of effective COVID treatments over the course of the pandemic⁴, and the severity of unequal
11 distribution of these treatments between racial groups, we aimed to assess the differences in treatment with remdesivir, as well
12 as LoS between Black and white patients using one of the most complete, timely, and highest quality aggregation of electronic
13 health records (EHR): the Truveta, Inc. data platform.

14 Remdesivir was the first antiviral given emergency use authorization by the US Food and Drug Administration (FDA)
15 on May 1, 2020 for demonstration of effectiveness in reducing LoS in hospitalized patients^{5,6}. It is an adenosine nucleoside
16 triphosphate analog that interferes with viral RNA-dependent RNA polymerase⁷. It has been shown to significantly reduce
17 COVID-related severity and duration of illness⁸. We focused on remdesivir because it is one of the most common COVID
18 treatments with emergency use authorization being granted early in the pandemic and treatment rates are well represented in
19 the Truveta dataset.

20 Electronic health record (EHR) data provide a comprehensive view of a patient's journey through COVID prophylaxis,
21 infection, symptomology, treatment, and ultimate outcome. Recent advances in data science, data security technology, and
22 ethical and legal reviews of data storage, processing, and distribution have allowed unprecedented access to such data stores.
23 For this study we aimed to examine the changes in delivery of COVID treatments and in-hospital LoS for COVID by race.

24 Results here show changes in differences between Black and white patient treatments with remdesivir and LoS with lower
25 rates of treatment and longer lengths of stay for Black patients in the early stages of the pandemic, but becoming statistically
26 indistinguishable during the Delta and Omicron waves after adjusting for a suite of potential comorbid confounders.

27 Methods

28 Study population

29 Our study included all inpatient COVID patients present in the de-identified Truveta electronic health records. Truveta provided
30 the de-identified medical records used in this study on June 22, 2022. Truveta is a collective of healthcare systems which
31 came together to aggregate EHR data with the purpose of enabling research. Currently this collective includes 24 members
32 who provide patient care in over 20,000 clinics and 700 hospitals across 43 states. Updated data is provided daily to Truveta.
33 Through syntactic normalization similar data fields from different systems are mapped to a common schema referred to as the
34 Truveta Data Model (TDM). Once organized into common fields, the values are normalized to common ontologies such as
35 ICD-10, SNOMED-CT, LOINC, RxNorm, CVX, etc., through semantic normalization. The normalization process employs an
36 expert-led, artificial intelligence driven process to accomplish high-confidence modeling at scale. The data are then de-identified
37 by expert determination under the HIPAA Privacy Rule. Once de-identified, the data are available for analysis in R or python
38 using Truveta Studio. The Providence Health Care Institutional Review Board has declared this study not human research
39 (STUDY2022000435). Our study period spanned from March 1, 2020 to March 1, 2022. Inclusion criteria included COVID-19
40 diagnosis, either from a lab result or an assigned diagnosis, during one of our treatment windows. Patients were excluded if their
41 records were missing sex, and age information. For those patients who were missing encounter times and for those patients who
42 received remdesivir, we excluded those patients missing drug administration times. The data provided by healthcare systems
43 was comprised of patients from 40 US states.

44 We compared three remdesivir treatment windows corresponding to waves of the pandemic: “December 2020” from
45 December 1, 2020 to February 28, 2021; “Delta” from June 1 to August 31, 2021; and “Omicron” from December 1 to February
46 28, 2021⁹. As remdesivir was given emergency authorization by the FDA on May 1, 2020, we included an additional wave –
47 “wild type” from March 1 to May 31, 2020 in the LoS analysis.

48 Our main comparisons were between remdesivir treatment between Black patients and white patients as well as LoS in
49 these two groups. Logistic regression with remdesivir treatment (yes/no) as the model outcome was used to estimate differences
50 between racial groups adjusting for age and sex, as well as the following comorbidities: diabetes, hypertension, chronic
51 kidney disease (CKD), liver disease, immunocompromised state, and cancer (ICD-10 and SNOMED codes are provided in
52 the Supplementary Material). Poisson and Negative Binomial generalized linear regression models were fit to counts of days
53 of LoS and compared by the Akaike information criterion (AIC)¹⁰ adjusting for the same covariates. We note that this is




Figure 1. Distribution of ages by age bin, and race.

54 exploratory and does not account for censoring in days of LoS as a full survival analysis would due to privacy limitations with
 55 data re-identification issues. A Kolmogorov-Smirnov test was used to test for differences in ages between Black patients and
 56 white patients.

57 All analyses were conducted in R Version 4.1.3¹¹, using packages dplyr¹², ggplot2¹³, gtools¹⁴, MASS¹⁵, xtable¹⁶,
 58 bit64¹⁷, and scales¹⁸.

59 Results

60 Of 556,134 patients who had a COVID diagnosis or lab test during one of the four pandemic periods of interest, 10.6% were
 61 inpatients, giving a final study population of 64,650 (Table 1). Females made up 51.2% of the inpatient sample, 14.6% Black,
 62 and 70.1% white. Due to the small proportion of Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific
 63 Islander, or patients missing data on race, we focus only on Black and white patients in these results. Near 46% of the population
 64 was over 65 years of age. The distributions of ages was significantly shifted to younger ages for Black patients than for white
 65 patients (Kolmogorov-Smirnov test, $D^+ = 0.159$, $p < 0.001$; Figure 1). Median age of hospitalizations for Black patients was
 66 58.7 years (25%–75% quantile: 44.5 – 69.9) compared to 65.4 years (25%–75% quantile: 51.5 – 76.9) for white patients. Both
 67 groups were matched on percentage with other prevalent comorbidities as the epidemic progressed (Table 2).




Figure 2. Distribution of ages by age bin, race, and pandemic wave.

68 Including adjustment for diabetes, hypertension, CKD, liver disease, immunocompromised state, and cancer, Black patients
69 received remdesivir at a statistically significant 12% during the December 2020 wave (Table 3 and Figure 3). No statistical
70 difference was seen for the Delta or Omicron waves, which were 9% lower and 7% lower odds than white patients, respectively.
71 Negative binomial models for days of LoS were preferred over Poisson models by AIC (Supplement). After adjustment for
72 age, sex, diabetes, hypertension, CKD, liver disease, immunocompromised state, and cancer, Black inpatients had 5%, 16%,
73 and 18% longer LoS for the wild type, December 2020, and Delta waves. There was no statistically significant difference for
74 the Omicron wave (3%) (Table 3 and Figure 3).

75 Discussion

76 Nearly all aspects of healthcare in our society have been affected disproportionately across SES, geography, and race or ethnic
77 group. Unfortunately, the COVID pandemic has seen the same patterns¹. Inequalities in access to healthcare, timeliness of
78 treatment delivery, and treatment outcomes have been known for decades¹⁹⁻²⁴. Our ongoing accumulation of knowledge on
79 COVID outcomes, epidemiology, and treatments allows us to better situate disparities across racial group. Here we find that
80 early in the pandemic there were broad differences in LoS and remdesivir treatments comparing Black patients and white
81 patients with comorbidities. Hearteningly, our sample of over 60 thousand COVID inpatients, shows this gap may be closing
82 and approaching parity between the two groups.

83 We examined the rates of comorbidities between Black and white patients in our sample and found statistical differences
84 for diabetes hypertension, CKD, liver disease, immunocompromised state, and cancer between race or ethnic groups that
85 attenuated over time (Table 1). In addition, we saw marked differences in the distribution of ages between groups who were
86 hospitalized; Black patients were hospitalized at ages nearly 10 years younger than white patients, and an overall left shift in
87 the age distribution for Black patients. This may indicate the earlier occurrence of the comorbidities in Black populations than
88 white populations. This has been seen for diabetes²⁵, hypertension^{26,27}, CKD²⁸, liver disease²⁹, and cancer^{30,31}. It could also
89 be due to other behavioral and social factors (e.g. smoking status, or access to primary care). Future work should examine in
90 more detail the drivers of this age discrepancy, and interventions implemented to reach younger Black individuals.

91 Geographic differences in susceptibility to COVID and treatment practice may also contribute to the disparities seen on
92 a national scale. For example, one study showed that environments with high particulate matter were positively correlated
93 with higher mortality in COVID³². COVID incidence peaked in different geographies at different times. Thus further study of
94 differences across geography with respect to race or ethnic group is warranted. We did not explicitly incorporate geography
95 into our analyses and leave that for future work.

96 Like all studies, ours is not without limitations. First, we compared only Black and white racial groups of patients for two
97 reasons: 1) while the Truveta platform has representative data on race or ethnic group, there are still sample size limitations to
98 race or ethnic groups other than Black and white; 2) there have been multiple studies examining various aspects in inequalities
99 between Black and white groups, but few or none using data as large and comprehensive as in the platform, and many are
100 from early in the pandemic^{1,3,33-37}. Second, our estimates of differences in LoS between race or ethnic groups are calculated
101 using Poisson and NB regression techniques which do not account for right- or left-censoring of LoS. Future work could use a
102 survival analysis approach to adjust for censoring. Third, we studied waves of the pandemic corresponding to the dominant
103 COVID strain at that time, and we do not include information on whether the patient had that dominant strain at the time.
104 That said, the intent of the study was to characterize differences in remdesivir treatment (chosen because of remdesivir's early
105 emergency use authorization and for having a large enough sample size in our data) and not the specific infecting strain type.
106 Fourth, we did not examine the potential effects of limitations in hospital capacity which may have exasperated disparities in
107 treatment. Future work should address geographic differences in disparities and local hospital capacity. Fifth, the data cannot
108 assess the time to diagnosis of COVID and the severity at admittance. Future studies should account for the full spectrum of
109 social determinants of health that drive an individual to seek healthcare. Finally, the inclusion criteria for this study included
110 individuals who had been hospitalized with a COVID infection, thus we cannot distinguish those admitted *for* COVID or those
111 admitted for *something else* and COVID was an ancillary diagnosis.

112 Despite these limitations, ours is a large study of over 60 thousand patients hospitalized with COVID and shows differences
113 in treatments and LoS between Black patients versus white patients. There are still many steps to be taken to achieve equity
114 in healthcare for all. Policymakers should prioritize continuing to understand where disparities exist and achieving equity in
115 access to healthcare and quality of care.




Figure 3. Logistic and NB regression results. A & B show the odds ratio for remdesivir treatment comparing Black to white inpatients. C & D show the risk ratio for LoS comparing Black to white inpatients. All analyses are adjusted for age, sex, diabetes, hypertension, CKD, liver disease, immunocompromised state, and cancer. Note the differences in y-axes between A & C and B & D.

116 Competing Interests

117 All authors are employees of Truveta, Incorporated.

118 Institutional Review Board Approval

119 The Providence Health Care Institutional Review Board has declared this study not human research (STUDY2022000435).

120 Data Availability Statement

121 Code necessary to generate all analyses and figures is included in a GitHub repository https://github.com/Truveta/alhouse_e_t_a_l_c_ovid_e_quity.

122 References

- 123 1. Khanijahani, A., Iezadi, S., Gholipour, K., Azami-Aghdash, S. & Naghibi, D. A systematic review of racial/ethnic and socioeconomic
124 disparities in covid-19. *Int. journal for equity health* **20**, 1–30 (2021).
- 125 2. Zelner, J. *et al.* Racial disparities in coronavirus disease 2019 (covid-19) mortality are driven by unequal infection risks. *Clin. Infect. Dis.*
126 **72**, e88–e95 (2021).
- 127 3. Mackey, K. *et al.* Racial and ethnic disparities in covid-19–related infections, hospitalizations, and deaths: a systematic review. *Annals*
128 *internal medicine* **174**, 362–373 (2021).
- 129 4. of Health, N. I. *et al.* Coronavirus disease 2019 (covid-19) treatment guidelines (2020).
- 130 5. Eastman, R. T. *et al.* Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of
131 covid-19. *ACS central Sci.* **6**, 672–683 (2020).
- 132 6. Beigel, J. H. *et al.* Remdesivir for the treatment of covid-19. *New Engl. J. Medicine* **383**, 1813–1826 (2020).
- 133 7. Jorgensen, S. C., Kebriaei, R. & Dresser, L. D. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience
134 for covid-19. *Pharmacother. The J. Hum. Pharmacol. Drug Ther.* **40**, 659–671 (2020).
- 135 8. Singh, S., Khera, D., Chugh, A., Khera, P. S. & Chugh, V. K. Efficacy and safety of remdesivir in covid-19 caused by sars-cov-2: a
136 systematic review and meta-analysis. *BMJ open* **11**, e048416 (2021).
- 137 9. Katella, K. Omicron, delta, alpha, and more: What to know about the coronavirus variants. *Yale Medicine*, 28th February, available at:
138 <https://www.yalemedicine.org/news/covid-19-variants-of-concern-omicron> (accessed 8th March, 2022) (2022).
- 139 10. Anderson, D. & Burnham, K. Model selection and multi-model inference. *Second. NY: Springer-Verlag* **63**, 10 (2004).
- 140 11. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria
141 (2022).
- 142 12. Wickham, H., François, R., Henry, L. & Müller, K. *dplyr: A Grammar of Data Manipulation* (2022). R package version 1.0.9.
- 143 13. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis* (Springer-Verlag New York, 2016).
- 144 14. Warnes, G. R., Bolker, B., Lumley, T. & team, C. *gtools: Various R Programming Tools* (2022). R package version 3.9.2.2.
- 145 15. Venables, W. N. & Ripley, B. D. *Modern Applied Statistics with S* (Springer, New York, 2002), fourth edn. ISBN 0-387-95457-0.
- 146 16. Dahl, D. B., Scott, D., Roosen, C., Magnusson, A. & Swinton, J. *xtable: Export Tables to LaTeX or HTML* (2019). R package version
147 1.8-4.
- 148 17. Oehlschlägel, J. & Silvestri, L. *bit64: A S3 Class for Vectors of 64bit Integers* (2020). R package version 4.0.5.
- 149 18. Wickham, H. & Seidel, D. *scales: Scale Functions for Visualization* (2020). R package version 1.1.1.
- 150 19. Burt, B. A. Fluoridation and social equity. *J. public health dentistry* **62**, 195–200, DOI: [10.1111/j.1752-7325.2002.tb03445.x](https://doi.org/10.1111/j.1752-7325.2002.tb03445.x) (2002).
151 Place: United States.
- 152 20. Aday, L. A. & Andersen, R. M. Equity of access to medical care: a conceptual and empirical overview. *Med. care* **19**, 4–27 (1981).
153 Place: United States.
- 154 21. Bull, C. N., Krout, J. A., Rathbone-McCuan, E. & Shreffler, M. J. Access and issues of equity in remote/rural areas. *The J. rural health : official journal Am. Rural. Heal. Assoc. Natl. Rural. Heal. Care Assoc.* **17**, 356–359, DOI: [10.1111/j.1748-0361.2001.tb00288.x](https://doi.org/10.1111/j.1748-0361.2001.tb00288.x) (2001).
155 Place: England.
- 156 22. Lichtenstein, B. & Weber, J. Losing Ground: Racial Disparities in Medical Debt and Home Foreclosure in the Deep South. *Fam. & community health* **39**, 178–187, DOI: [10.1097/FCH.000000000000108](https://doi.org/10.1097/FCH.000000000000108) (2016). Place: United States.
- 157 23. Dickman, S. L. *et al.* Trends in Health Care Use Among Black and White Persons in the US, 1963–2019. *JAMA network open* **5**,
158 e2217383, DOI: [10.1001/jamanetworkopen.2022.17383](https://doi.org/10.1001/jamanetworkopen.2022.17383) (2022).
- 159
- 160

- 161 **24.** Ruther, M. & Dobson, A. Equal treatment and unequal benefits: a re-examination of the use of Medicare services by race, 1967-1976.
162 *Heal. care financing review* **2**, 55–83 (1981).
- 163 **25.** Ogunwole, S. M. & Golden, S. H. Social determinants of health and structural inequities—root causes of diabetes disparities. *Diabetes*
164 *Care* **44**, 11–13 (2021).
- 165 **26.** Hardy, S. T. *et al.* Racial and ethnic differences in blood pressure among us adults, 1999–2018. *Hypertension* **78**, 1730–1741 (2021).
- 166 **27.** Dorans, K. S., Mills, K. T., Liu, Y. & He, J. Trends in prevalence and control of hypertension according to the 2017 american college of
167 cardiology/american heart association (acc/aha) guideline. *J. Am. Hear. Assoc.* **7**, e008888 (2018).
- 168 **28.** Hsiung, J.-T. *et al.* Cardiovascular mortality and hospitalization risk with ldl by ckd stage in african-american and white us veterans. *J.*
169 *Clin. Lipidol.* **15**, e22–e23 (2021).
- 170 **29.** Wang, Q., Davis, P. B. & Xu, R. Covid-19 risk, disparities and outcomes in patients with chronic liver disease in the united states.
171 *EClinicalMedicine* **31**, 100688 (2021).
- 172 **30.** Giaquinto, A. N. *et al.* Cancer statistics for african american/black people 2022. *CA: A Cancer J. for Clin.* **72**, 202–229 (2022).
- 173 **31.** Smith, R. A. *et al.* Cancer screening in the united states, 2019: A review of current american cancer society guidelines and current issues
174 in cancer screening. *CA: a cancer journal for clinicians* **69**, 184–210 (2019).
- 175 **32.** Wu, X., Nethery, R. C., Sabath, M. B., Braun, D. & Dominici, F. Air pollution and covid-19 mortality in the united states: Strengths and
176 limitations of an ecological regression analysis. *Sci. advances* **6**, eabd4049 (2020).
- 177 **33.** Tirupathi, R. *et al.* Covid-19 disparity among racial and ethnic minorities in the us: a cross sectional analysis. *Travel. medicine infectious*
178 *disease* **38**, 101904 (2020).
- 179 **34.** Benitez, J., Courtemanche, C. & Yelowitz, A. Racial and ethnic disparities in covid-19: evidence from six large cities. *J. Econ. Race,*
180 *Policy* **3**, 243–261 (2020).
- 181 **35.** Yancy, C. W. Covid-19 and african americans. *Jama* **323**, 1891–1892 (2020).
- 182 **36.** Wang, Q., Berger, N. A. & Xu, R. Analyses of risk, racial disparity, and outcomes among us patients with cancer and covid-19 infection.
183 *JAMA oncology* **7**, 220–227 (2021).
- 184 **37.** Marmarchi, F. *et al.* Clinical outcomes of critically ill patients with covid-19 by race. *J. racial ethnic health disparities* **9**, 385–389
185 (2022).

	Wild (N=5803)	Dec2020 (N=17824)	Delta (N=12287)	Omicron (N=28736)	Overall (N=64650)
Sex					
Female	2840 (48.9%)	8781 (49.3%)	6355 (51.7%)	15094 (52.5%)	33070 (51.2%)
Male	2963 (51.1%)	9043 (50.7%)	5932 (48.3%)	13642 (47.5%)	31580 (48.8%)
Race					
American Indian or Alaska Native	27 (0.5%)	102 (0.6%)	107 (0.9%)	229 (0.8%)	465 (0.7%)
Asian	177 (3.1%)	522 (2.9%)	244 (2.0%)	615 (2.1%)	1558 (2.4%)
Black or African American	1339 (23.1%)	2537 (14.2%)	1594 (13.0%)	3991 (13.9%)	9461 (14.6%)
Native Hawaiian or Other Pacific Islander	18 (0.3%)	64 (0.4%)	68 (0.6%)	112 (0.4%)	262 (0.4%)
White	3393 (58.5%)	12553 (70.4%)	8789 (71.5%)	20602 (71.7%)	45337 (70.1%)
Missing	849 (14.6%)	2046 (11.5%)	1485 (12.1%)	3187 (11.1%)	7567 (11.7%)
Ethnicity					
Hispanic or Latino	889 (15.3%)	2985 (16.7%)	1994 (16.2%)	3536 (12.3%)	9404 (14.5%)
Not Hispanic or Latino	4670 (80.5%)	14350 (80.5%)	9897 (80.5%)	24250 (84.4%)	53167 (82.2%)
Missing	244 (4.2%)	489 (2.7%)	396 (3.2%)	950 (3.3%)	2079 (3.2%)
Age bracket					
[0,5)	12 (0.2%)	42 (0.2%)	55 (0.4%)	209 (0.7%)	318 (0.5%)
[05,10)	3 (0.1%)	18 (0.1%)	25 (0.2%)	63 (0.2%)	109 (0.2%)
[10,15)	3 (0.1%)	30 (0.2%)	30 (0.2%)	68 (0.2%)	131 (0.2%)
[15,18)	7 (0.1%)	44 (0.2%)	47 (0.4%)	124 (0.4%)	222 (0.3%)
[18,20)	22 (0.4%)	69 (0.4%)	82 (0.7%)	186 (0.6%)	359 (0.6%)
[20,25)	79 (1.4%)	316 (1.8%)	379 (3.1%)	825 (2.9%)	1599 (2.5%)
[25,30)	137 (2.4%)	451 (2.5%)	605 (4.9%)	1296 (4.5%)	2489 (3.9%)
[30,35)	181 (3.1%)	589 (3.3%)	783 (6.4%)	1588 (5.5%)	3141 (4.9%)
[35,45)	452 (7.8%)	1340 (7.5%)	1597 (13.0%)	2508 (8.7%)	5897 (9.1%)
[45,55)	831 (14.3%)	2272 (12.7%)	2043 (16.6%)	3259 (11.3%)	8405 (13.0%)
[55,65)	1218 (21.0%)	3577 (20.1%)	2403 (19.6%)	5368 (18.7%)	12566 (19.4%)
[65,75)	1241 (21.4%)	4023 (22.6%)	2097 (17.1%)	5952 (20.7%)	13313 (20.6%)
[75,85)	996 (17.2%)	3292 (18.5%)	1467 (11.9%)	4769 (16.6%)	10524 (16.3%)
[85,Inf)	621 (10.7%)	1761 (9.9%)	674 (5.5%)	2521 (8.8%)	5577 (8.6%)
Treated with Remdesivir					
Yes	222 (3.8%)	6948 (39.0%)	4716 (38.4%)	4833 (16.8%)	16719 (25.9%)
No	5581 (96.2%)	10876 (61.0%)	7571 (61.6%)	23903 (83.2%)	47931 (74.1%)
Cancer					
Yes	318 (5.5%)	965 (5.4%)	626 (5.1%)	1870 (6.5%)	3779 (5.8%)
No	5485 (94.5%)	16859 (94.6%)	11661 (94.9%)	26866 (93.5%)	60871 (94.2%)
Chronic kidney disease (CKD)					
Yes	379 (6.5%)	1432 (8.0%)	738 (6.0%)	2197 (7.6%)	4746 (7.3%)
No	5424 (93.5%)	16392 (92.0%)	11549 (94.0%)	26539 (92.4%)	59904 (92.7%)
Diabetes					
Yes	1033 (17.8%)	3353 (18.8%)	1931 (15.7%)	4774 (16.6%)	11091 (17.2%)
No	4770 (82.2%)	14471 (81.2%)	10356 (84.3%)	23962 (83.4%)	53559 (82.8%)
Hypertension					
Yes	2113 (36.4%)	6617 (37.1%)	3941 (32.1%)	10382 (36.1%)	23053 (35.7%)
No	3690 (63.6%)	11207 (62.9%)	8346 (67.9%)	18354 (63.9%)	41597 (64.3%)
Liver disease					
Yes	219 (3.8%)	668 (3.7%)	564 (4.6%)	1557 (5.4%)	3008 (4.7%)
No	5584 (96.2%)	17156 (96.3%)	11723 (95.4%)	27179 (94.6%)	61642 (95.3%)
Immunocompromised					
Yes	405 (7.0%)	1208 (6.8%)	831 (6.8%)	2468 (8.6%)	4912 (7.6%)
No	5398 (93.0%)	16616 (93.2%)	11456 (93.2%)	26268 (91.4%)	59738 (92.4%)

Table 1. Demographic characteristics of the population affected by each wave of COVID-19 and their comorbidities (the age distributions are given in Figure 2).

Race	Comorbidity	Wild	Dec. 2020	Delta	Omicron	Overall
Black or African American	Cancer	52 (3.88%)	115 (4.53%)	56 (3.51%)	195 (4.89%)	418 (4.42%)
White	Cancer	235 (6.93%)	774 (6.17%)	502 (5.71%)	1486 (7.21%)	2997 (6.61%)
Black or African American	CKD	107 (7.99%)	328 (12.93%)	132 (8.28%)	412 (10.32%)	979 (10.35%)
White	CKD	217 (6.4%)	974 (7.76%)	504 (5.73%)	1565 (7.6%)	3260 (7.19%)
Black or African American	Diabetes	273 (20.39%)	603 (23.77%)	281 (17.63%)	772 (19.34%)	1929 (20.39%)
White	Diabetes	566 (16.68%)	2251 (17.93%)	1340 (15.25%)	3342 (16.22%)	7499 (16.54%)
Black or African American	Hypertension	541 (40.4%)	1069 (42.14%)	575 (36.07%)	1574 (39.44%)	3759 (39.73%)
White	Hypertension	1283 (37.81%)	4774 (38.03%)	2887 (32.85%)	7697 (37.36%)	16641 (36.71%)
Black or African American	Immunocompromised	79 (5.9%)	158 (6.23%)	96 (6.02%)	313 (7.84%)	646 (6.83%)
White	Immunocompromised	285 (8.4%)	936 (7.46%)	636 (7.24%)	1876 (9.11%)	3733 (8.23%)
Black or African American	Liver disease	34 (2.54%)	74 (2.92%)	65 (4.08%)	161 (4.03%)	334 (3.53%)
White	Liver disease	138 (4.07%)	474 (3.78%)	405 (4.61%)	1165 (5.65%)	2182 (4.81%)

Table 2. Percentages of each population (Black patients and white patients) for each comorbidity (the age distributions are given in Figure 2) by COVID wave.

Wave	Population	Estimate	2.5%	97.5%
Dec2020	Black or African American	0.88	0.80	0.96
Delta	Black or African American	0.91	0.81	1.01
Omicron	Black or African American	0.93	0.84	1.02

Table 3. Odds Ratio and 95% confidence interval for remdesivir treatment while hospitalized for COVID comparing Black to white inpatients. Adjusted for age, sex, diabetes, hypertension, CKD, liver disease, immunocompromised state, and cancer.

Wave	Population	Estimate	2.5%	97.5%
Wild	Black or African American	1.13	1.06	1.21
Dec2020	Black or African American	1.17	1.12	1.23
Delta	Black or African American	1.14	1.07	1.21
Omicron	Black or African American	1.03	0.99	1.07

Table 4. Table shows the Risk Ratio of Length of Stay (LoS) for Black inpatients as compared to white inpatients. Adjusted for age, sex, diabetes, hypertension, CKD, liver disease, immunocompromised state, and cancer.